Ranbaxy strengthens as its arm receives approval to market RAN Donepezil in Canada

08 Jan 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 482.60, up by 1.65 points or 0.34% from its previous closing of Rs. 480.95 on the BSE.

The scrip opened at Rs. 483.70 and has touched a high and low of Rs. 485.50 and Rs. 476.00 respectively. So far 85798 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 514.20 on 08-Jan-2013 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 490.15 and Rs. 456.00 respectively. The current market cap of the company is Rs. 20290.88 crore.

The promoters holding in the company stood at 63.51% while Institutions and Non-Institutions held 19.46% and 14.29% respectively.

Ranbaxy Laboratories' wholly owned subsidiary Ranbaxy Pharmaceuticals Canada Inc. (RPCI), has received an approval on December 24, 2013 to manufacture and market RAN-Donepezil Hydrochloride 5 mg and 10 mg tablets from Health Canada.

The total market size of Aricept (Donepezil Hydrochloride) in Canada is $153.9 million and growing at 38% (extended units). Donepezil Hydrochloride is indicated in the treatment of dementia in Alzheimer’s patients.

Ranbaxy Pharmaceuticals Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company. RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×